Patents Examined by Daniel E. Kolker
  • Purification of biological molecules
    Patent number: 10865224
    Abstract: The present invention relates to improved processes and systems for purification of biological molecules, where the processes can be performed in a continuous manner.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: December 15, 2020
    Assignee: EMD Millipore Corporation
    Inventors: Alex Xenopoulos, Michael Phillips, Wilson Moya, Jad Jaber, Mikhail Kozlov, Ajish Potty, Matthew T. Stone, William Cataldo, Christopher Gillespie
  • Method for purifying composition comprising antibodies with anionic polymer
    Patent number: 10858391
    Abstract: A composition containing an antibody is prepared in such a state that the composition contains an anionic polymer at pH lower than the pI of the antibody, and impurities insolubilized by the anionic polymer are removed. More preferably, the composition is prepared in such a state that the composition contains an anionic polymer at pH lower than or equal to the pI of the antibody minus one, and impurities insolubilized by the anionic polymer are removed.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: December 8, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Seiya Ito, Akihiro Yanagita
  • Affinity separation matrix for purifying protein containing immunoglobulin K chain variable region
    Patent number: 10858392
    Abstract: An affinity separation matrix includes a water-insoluble base material; and a ligand that is immobilized on the water-insoluble base material, wherein the ligand is an antibody ? chain variable region-binding peptide comprising B5 domain of Protein L derived from Peptostreptococcus magnus 312 strain or a part thereof.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: December 8, 2020
    Assignee: KANEKA CORPORATION
    Inventors: Shinichi Yoshida, Dai Murata
  • Immunoglobulins and uses thereof
    Patent number: 10858413
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 8, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Mark J. Wall, Yue-Mei Zhang, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Ellen Chi
  • Method for purifying antibody or antibody fragment containing ?-chain variable region
    Patent number: 10844112
    Abstract: A method for purifying an antibody or an antibody fragment containing ?-chain variable region includes adsorbing at least one of the antibody or the antibody fragment onto an affinity separation matrix by contacting a liquid sample with the affinity separation matrix, washing the affinity separation matrix to remove impurities, and separating the at least one of the antibody or the antibody fragment from the affinity separation matrix by using an acetate buffer. The liquid sample includes the at least one of the antibody or the antibody fragment. The affinity separation matrix includes a water-insoluble carrier and a ligand selected from the group consisting of Protein L, a variant of Protein L, a domain of Protein L, and a variant of the domain. The ligand is immobilized on the water-insoluble carrier.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: November 24, 2020
    Assignee: KANEKA CORPORATION
    Inventors: Dai Murata, Shinichi Yoshida, Kazunobu Minakuchi
  • Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
    Patent number: 10822421
    Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: November 3, 2020
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Brian Wong, Emma Masteller, Kris Reedquist
  • Immunoglobulin-binding proteins and their use in affinity purification
    Patent number: 10808042
    Abstract: The present disclosure relates to non-natural binding proteins comprising one or more non-natural immunoglobulin (Ig) binding domains wherein at least one non-natural lg-binding domain comprises the amino acid sequence X1 X2X3XiXsX5X7 XsQQX11AFYX1sX15LX1 sX19PX21 LX23X24X2sQRX28X2gf IQSLKDDPSXio SXi2Xi3Xi4LXi5EAXigKLXs2Xs3Xs4QXs5PX. The disclosure also relates to compositions such as affinity matrices comprising the non-natural Ig-binding proteins of the invention. Use of these Ig-binding proteins or of the compositions for affinity purification of immunoglobulins and to methods of affinity purification.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: October 20, 2020
    Assignee: Navigo Proteins GmbH
    Inventor: Ulrich Haupts
  • Mutant immunoglobulin K chain variable region-binding peptide
    Patent number: 10808013
    Abstract: A first immunoglobulin ? chain variable region-binding peptide includes an amino acid sequence of SEQ ID NO: 21 with substitution of one or more amino acid residues at the 15th position, the 16th position, the 17th position or the 18th position, wherein an acid dissociation pH thereof is shifted to a neutral side. A second immunoglobulin ? chain variable region-binding peptide further includes deletion, substitution and/or addition of 1-20 amino acid residues at positions other than the 15th position, the 16th position, the 17th position and the 18th position. A third immunoglobulin ? chain variable region-binding peptide includes an amino acid sequence with a sequence identity of 80% or more to the amino acid sequence of the first immunoglobulin ? chain variable region-binding peptide.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: October 20, 2020
    Assignee: KANEKA CORPORATION
    Inventor: Shinichi Yoshida
  • Activated carbon for the removal of leachables and/or extractables
    Patent number: 10793592
    Abstract: The present invention relates to the purification of target molecules like recombinant and/or biotherapeutic proteins. Activated carbon can be used to remove leachables and/or extractables resulting from disposable equipment employed in the process.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: October 6, 2020
    Assignee: Merck Patent GmbH
    Inventors: Romas Skudas, Klaus Adrian, Bianca Edlemann, Sven Andrecht, Wilson Moya
  • Continuous multistep process for purifying antibodies
    Patent number: 10793622
    Abstract: The invention provides a three-step chromatography process for small and large-scale purification of proteins, specifically monoclonal antibodies, using only four buffer solutions made from a mother solution.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: October 6, 2020
    Assignee: SANOFI
    Inventors: Didier Duthe, Celine Hemet, Laure Landric-Burtin, Benoit Mothes
  • Anti-TNF?-antibodies and functional fragments thereof
    Patent number: 10787508
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 29, 2020
    Assignee: Numab Innovation AG
    Inventors: Tea Gunde, Sebastian Meyer
  • Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
    Patent number: 10787500
    Abstract: Methods for purifying multispecific antibodies on interest (MAIs) that co-engage at least two different antigens or epitopes (also referred to targets, used interchangeably throughout), from compositions comprising the MAI and parental homodimeric antibody species are provided, as well as reagents which may be used to practice such methods.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: September 29, 2020
    Assignee: Adimab, LLC
    Inventors: Juergen Hermann Nett, K. Dane Wittrup, Maximiliano Vasquez
  • Use of interleukin-22 in the treatment of fatty liver disease
    Patent number: 10786551
    Abstract: The present invention relates to use of interleukin-22 (IL-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of IL-22 in decreasing the levels of transaminases is also provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: September 29, 2020
    Assignee: Generon (Shanghai) Corporation Ltd.
    Inventors: Yu Liang Huang, Zhi Hua Huang, Qi Sun
  • Anti-TNF?-antibodies and functional fragments thereof
    Patent number: 10774140
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 15, 2020
    Assignee: Numab Therapeutics AG
    Inventors: Tea Gunde, Sebastian Meyer
  • Affinity support and method for isolating immunoglobulin
    Patent number: 10766924
    Abstract: To provide an affinity support in which a binding property of a ligand to a target substance is improved. The affinity support contains a solid phase support and a protein ligand, wherein the protein ligand is represented by formula (1): R—R1 (1) wherein R represents a linker binding to the solid phase support, which contains a polyproline, and R1 represents a protein showing an affinity to immunoglobulin, and the R is bound to a C terminal or an N terminal of an amino acid sequence in R1.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: September 8, 2020
    Assignees: JSR CORPORATION, JSR LIFE SCIENCES CORPORATION
    Inventors: Takashi Ichii, Satoshi Nakamura, Jun-ichi Yasuoka, Kaori Itaya, Tomonori Shiotani
  • Anti-TNF-alpha-antibodies and functional fragments thereof
    Patent number: 10759852
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 1, 2020
    Assignee: Numab Innovation AG
    Inventors: Tea Gunde, Sebastian Meyer
  • Anti-CD25 antibody agents
    Patent number: 10752691
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 25, 2020
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • IL-26 inhibitors
    Patent number: 10751416
    Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with interleukin 26 (IL-26), including inflammatory diseases, such as psoriasis and/or bacterial infections.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: August 25, 2020
    Assignees: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV), BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Michel Gilliet, Jeremy Di Domizio, Stephan Meller
  • Anti-CD25 antibody agents
    Patent number: 10745485
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 18, 2020
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • Anti-CD25 antibody agents
    Patent number: 10738125
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 11, 2020
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz